$15.2 Million Infusion from International Investors Rounds Out Financing; Funds Will Support Landmark Trial, Expand Commercial Operations KIRKLAND, Wash., March 11, 2015 — Cardiac Dimensions® today announced the addition of $15.2 million to its previously announced financing. Life …
Latest News From Lumira Ventures
Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System
Third Multi-Center Study Shows Compelling Results Consistent with Previous Trials; Data Presented at TCT KIRKLAND, Wash., Sept. 17, 2014 /PRNewswire/ — Cardiac Dimensions®, Inc. today announced that new long-term outcomes data from the TITAN II clinical trial of …
Cardiac Dimensions® Completes $20 Million Equity Financing
Funding Will Enable Initiation of Blinded Randomized Clinical Trial and Expanded Commercialization of CARILLON® Mitral Contour System® (KIRKLAND, WA), April 16, 2014 — Cardiac Dimensions® Inc. today announced the completion of a $20 million financing. M. H. Carnegie …
Cardiac Dimensions® Receives Positive Reimbursement Decision For 120 Hospitals Across Germany
Sets Stage for Expanded Adoption Of CARILLON® Mitral Contour System® (KIRKLAND, WA), February 19, 2014—Cardiac Dimensions®, Inc. today announced that the Company’s CARILLON® Mitral Contour System® has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 1 approval across …
Cardiac Dimensions® Completes Patient Enrollment in TITAN II Clinical Trial
Third European Multi-Center Study Validating Earlier Compelling Results KIRKLAND, Wash., March 8, 2013 /PRNewswire/ — Cardiac Dimensions®, Inc. today announced that it has completed enrollment in its TITAN II clinical trial, a follow-up to the landmark TITAN clinical trial …
Cardiac Dimensions® Initiates European Commercialization of CARILLON® Mitral Contour System®
Commercial Rollout includes PRIME Study, Collecting Data on up to 300 European Patients (KIRKLAND, WA), September 28, 2012—Cardiac Dimensions®, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON® …
Cardiac Dimensions Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Data Shows Safety, Efficacy of CARILLON® System; Paves Way for European Launch KIRKLAND, Wash., May 21, 2012 /PRNewswire/ — Cardiac Dimensions®, Inc. today announced that data from its landmark TITAN clinical trial has been published in the most …
Cardiac Dimensions Announces First Patient Treated In TITAN II Clinical Trial
Learn More-External Link
Cardiac Dimensions® Receives CE Mark Approval For Enhanced CARILLON® Mitral Contour System™
Learn More-External Link
Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
Trial to Assess Safety, Efficacy of CARILLON® Mitral Contour System for Treating Heart Failure Patients Suffering from Functional Mitral Regurgitation KIRKLAND, Wash., Aug. 18 /PRNewswire/ — Cardiac Dimensions, an early stage company focused on the development of minimally …
Cardiac Dimensions® Inc. Receives 2009 Best of Kirkland Award
Learn More-External Link
Device Offers Hope for Patients With Leaky Heart Valve – Forbes
May be option for those too sick for open-heart surgery, study suggests THURSDAY, May 7 (HealthDay News) — A new device offers hope for patients with a leaky heart valve who are too sick for open-heart surgery, …
Intriguing early results for device that reshapes enlarged, leaky heart valve
A fast, simple treatment option for patients too sick for surgery? LAS VEGAS, NV (May 7 2009) — An innovative device that acts like a belt to reshape an enlarged, leaky heart valve is providing a minimally invasive …